Table 6.
Relationship Between BH3 Peptide Priming Biomarkers and Clinical pathologic Information Relative to Patient Response to Study Therapy
| A. BH3 Profiling Biomarkers Association with Response | |||||
|---|---|---|---|---|---|
| Mean %Priming ± SD | p-value (Mann-Whitney) |
AUC [95% CI] |
p-value (AUC) |
||
| Non-Responders | Responders | ||||
| Bad (100 µM) | 54.8 ± 9.3 | 61.3 ± 20.0 | 0.13 | 0.69 [0.19, 0.84] | 0.090 |
| Bim (0.1 µM) | 5.5 ± 6.1 | 7.7 ± 12.1 | 0.95 | 0.51 [0.29, 0.73] | 0.92 |
| Hrk (100 µM) | 41.2 ± 20.1 | 48.6 ± 25.9 | 0.36 | 0.61 [0.38, 0.85] | 0.35 |
| Noxa (100 µM) | 26.8 ± 12.0 | 34.4 ± 21.9 | 0.43 | 0.60 [0.38, 0.82] | 0.38 |
| Puma (100 µM) | 72.4 ± 14.9 | 77.1 ± 12.8 | 0.42 | 0.60 [0.37, 0.83] | 0.40 |
| Puma (10 µM) | 22.3 ± 9.9 | 32.8 ± 16.5 | 0.059 | 0.73 [0.53, 0.93] | 0.027 |
| B. Clinical Patient Information Association with Response | |||
|---|---|---|---|
| p-value (Mann-Whitney) |
AUC [95% CI] |
p-value (AUC) |
|
| Age (median=60; range 26–74) | 0.99 | 0.51[0.28,0.74] | 0.93 |
| Gender | 1.00 | 0.51[0.30, 0.72] | 0.90 |
| RAI Stage | 0.87 | 0.52[0.33, 0.70] | 0.86 |
| # Prior Therapies | 0.61 | 0.57[0.35, 0.80] | 0.52 |
| Fludarabine Refractory | 0.66 | 0.57[0.53, 0.84] | 0.45 |
| Bulky Disease (>5cm) | 0.088 | 0.68[0.53, 0.84] | 0.022 |
| Bulky Disease (>10cm) | 0.25 | 0.60[0.50, 0.70] | 0.053 |
| Dose Level | 0.41 | 0.60[0.37, 0.84] | 0.38 |
| Tumor Lysis Syndrome (TLS) | 0.54 | 0.57[0.43, 0.71] | 0.35 |